The latest price target for AtriCure (NASDAQ:ATRC) was reported by Canaccord Genuity on October 30, 2024. The analyst firm set a price target for $53.00 expecting ATRC to rise to within 12 months (a possible 48.54% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by Canaccord Genuity, and AtriCure maintained their buy rating.

The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.

There is no last downgrade for AtriCure.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on October 30, 2024 so you should expect the next rating to be made available sometime around October 30, 2025.

While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a maintained with a price target of $49.00 to $53.00. The current price AtriCure (ATRC) is trading at is $35.68, which is out of the analyst’s predicted range.